Fat Reduce and Weight Loss Drugs Orlistat CAS 96829-58-2 Fat Burning Steroid
Quick details:
Model NO.:96829-58-2
Product Name:Orlistat
Other Name:Orlistat
CAS No.:96829-58-2
Assay:98%
M.F.:C18H22O2
M.W.:270.37
Appearance:White Power
Paacking:Foil Bag
Delivery:Within 24hours After Your Payment
Express:TNT, UPS, DHL, EMS, Hkems, FedEx
Export Markets:Global
Packing:Foil Bag
Standard:GMP
Origin:China
HS Code:3001200020
Production Capacity:1000kg/Mouth
Orlistat Description :
Orlistat is a non-systemic effects of anti-obesity drugs for specific gastrointestinal lipase
inhibitor, combined with dietary restrictions can help promote weight loss and prevent
weight regain. Gastrointestinal lipases break down fats in the gastrointestinal tract is
necessary enzymes, orlistat inhibits stomach, pancreatic and hydroxy acid esterase,
primarily through the stomach, small intestine lumen of the stomach and pancreatic
lipases active serine parts form a covalent bond, to inactivate enzymes play a therapeutic
role. Inactivate enzymes can not be fat in food (mainly triglyceride) hydrolysis of absorbable
and non-esterified fatty acid monoacylglycerol. No decomposition of triglycerides (about 30%
of the amount of feed) can not be absorbed in the intestine, thereby reducing caloric intake,
body weight under control. Systemic absorption of the drug efficacy can play without going
through. Orlistat for weight loss, and reduce the risk factors associated with obesity and other
diseases associated with obesity (including high cholesterol, type 2 diabetes, impaired glucose
tolerance, hyperinsulinemia, hypertension) in morbidity, and reduce the fat content of
organs.
Application:
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data
from clinical trials suggest that people given orlistat in addition to lifestyle modifications,
such as diet and exercise, lose about 2-3 kilograms (4.4
6.6 lb) more than those not taking the drug over the course of a year.Orlistat also
modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes,
whether due to weight loss itself or to other effects; in a large randomized controlled trial,
orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment
effects), which can include steatorrhea (oily, loose stools). These decrease with time,
however, and are the most frequently reported adverse effects of the drug. In the United
States and the European Union, orlistat is available for sale without a prescription. Over-the
counter approval was controversial in the United States, with consumer advocacy group
Public Citizen repeatedly opposing it on safety and efficacy grounds. Generic formulations
of orlistat are available in some countries. A prescription is needed for use in Australia.
Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed
as a prescription drug under the trade name by Roche in most countries, and is sold
over-the-counter as by GlaxoSmithKline in the United Kingdom and the United States.Its primary
function is preventing the absorption of fats from the human diet by acting as a lipase
inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a
healthcare provider-supervised reduced-calorie diet.
Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases
isolated from the bacterium Streptomyces toxytricini.However, due to its relative simplicity
and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data
from clinical trials suggest that people given orlistat in addition to lifestyle modifications,
such as diet and exercise, lose about 2-3 kilograms (4.46.6 lb) more than those not
taking the drug over the course of a year.Orlistat also modestly
reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due
to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was
found to reduce the incidence of diabetes by nearly 40% in obese people.
Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment
effects), which can include steatorrhea (oily, loose stools). These decrease with time, however,
and are the most frequently reported adverse effects of the drug.In the United States and
the European Union,orlistat is available for sale without a prescription. Over-
the counter approval was controversial in the United States, with consumer advocacy group
Public Citizen repeatedly opposing it on safety and efficacy grounds.Generic formulations of
orlistat are available in some countries. In Australia it is listed as an S3 medication, which
means it’s available over the counter in pharmacies.At times, such as in spring 2012, orlistat
has come into short supply, with consequent price increases because of nonavailability of one
of the drug’s components.
Medical uses
Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat
varies.In one year clinical trials, between 35.5% and 54.8% of subjects achieved a 5%
or greater decrease in body mass, although not all of this mass was necessarily fat. Between
16.4% and 24.8% achieved at least a 10% decrease in body fat.After orlistat was stopped, a
significant number of subjects regained weight-
up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese
population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).
Long-term use of orlistat also leads to a modest
reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic
blood pressure respectively).
Contact Now
